| Revenue growth | 37.6% YoY consolidated growth for FY26. |
|---|---|
| Margins | Consolidated EBITDA margin at 6.64% for FY26. |
| Order book | Participating in national tenders (e.g., Bolivia, Nicaragua). |
| Demand visibility | Strong, driven by 850+ dossier ready-to-file products. |
| Management confidence | High; expanding D2C channels and global footprint. |
Growth
FY26 Consolidated Revenue grew 37.6% to ₹8,536 Mn; EBITDA increased 24.1% to ₹567 Mn; PAT rose 20.2% to ₹462 Mn.
Outlook
Targeting 200+ B2C launches, 2,100+ new filings, and entry into 5+ new territories including Eastern Europe and ASEAN.
Risks
Expansion into new semi-regulated territories involves inherent regulatory audit and compliance hurdles across 40+ countries.
Earnings Call filed with NSE, NSE: REMUS. Summary written with AI assistance from the document.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹946.00
- Market cap
- ₹1,115 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 30.1×Sector 50.4×
- Promoter holding
- 70.95%
- FII holding
- 5.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Remus Pharmaceuticals Management Change
Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.
Remus Pharmaceuticals SME to Main Board Migration
Remus Pharmaceuticals' board approved the company's migration from the NSE SME Emerge platform to the Main Board. It also announced a new subsidiary in the Dominican Republic.
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals delivered 38% YoY consolidated revenue growth for FY26. Management is shifting focus toward higher-margin B2C segments and niche formulations in Latin America and Southeast Asia.